KOBAYASHI I, MURAOKA H, MATSUZAKI K, SAIKA T, HASEGAWA M, AKITA H, IWATA S, SATO Y, SUNAKAWA K; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 57 (abstract no. 798).
Chemotherapy Div., Mitsubishi Kagaku Bio-Clin. Lab., Inc., Tokyo, JAPAN
OBJECTIVE: Escherichia coli O157:H7 is the major cause of outbreak of bloody diarrhea or causes hemolytic-uremic syndrome sporadically which are clinically the most important and lead to life-threatening sequelae. The antimicrobial activity of fosfomycin (FOM) was determined against 78 clinical isolates of E. coli O157:H7. The therapeutic effect of FOM at oral dose against intestinal infection with E. coli O157:H7 was investigated in a mouse model.METHOD: The MICs of FOM against 78 strains of E. coli O157:H7 were determined by the agar dilution method, according to NCCLS. Six ICR (IQI, germ free) mice aged 5 weeks were challenged orally with an E. coli O157:H7. FOM was given at an oral dose of 600 mg/kg twice a day for 6 days to 3 mice infected with E. coli O157:H7 from 3 days after challenge to investigate changes in viable cell counts.RESULTS: MICs of FOM ; FOM was active against E. coli O157:H7 tested with MIC90 of 2microg/ml, and its MIC range was 1-2microg/ml. Mouse model; The viable cells decreased markedly from about 10[10 ]CFU/g before dosing to 10[3]-10[4 ]CFU/g on day 1 of dosing, and no viable cells were detected in the feces from day 2 of dosing onwards. During the period, no verotoxin was detected in fecal samples collected from the 6 mice (including 3 controls).CONCLUSION: These results suggest that FOM was active against E. coli O157:H7 and a marked decrease in viable cells without the liberation of verotoxin was observed in the feces of mice infected E. coli O157:H7 after FOM was given orally.
Publication Types:
Keywords:
- Animals
- Escherichia coli O157
- Feces
- Fosfomycin
- Humans
- In Vitro
- Mice
- Muridae
- Shiga Toxin 1
- Shiga Toxins
- utilization
Other ID:
UI: 102244783
From Meeting Abstracts